Expert Radar
Dr. Vandana Abramson, MD, MSTR
Physician, Vanderbilt Health (Nashville, TN)
Bachelor of Arts, University of California, Berkeley
Dr. Vandana G. Abramson has 17 years of experience in the field of Medical Oncology. She earned her BA in English, as well as Molecular and Cellular Biology from the University of California, Berkeley, her MD from the University of Chicago Pritzker School of Medicine, and her MSTR from the University of Pennsylvania. After completing her residency in Medicine at Brigham and Women's Hospital, she went on to complete her fellowship in Hematology and Oncology at the Perelman School of Medicine at the University of Pennsylvania. Today, this expert is board-certified in Medical Oncology. Formerly, this expert served as the Director of Inpatient Oncology at the Vanderbilt University School of Medicine. She currently serves as a Professor of Hematology and Oncology and as the Donna S. Hall Chair of Breast Cancer at the Vanderbilt University School of Medicine. She is also a Co-Leader of the Breast Cancer Research Program at Vanderbilt-Ingram Cancer Center and a Medical Oncologist with Vanderbilt Health.
v*********@v****.org
(917) ***-****
Nashville, Tennessee
Get a FREE Demo of Dr. Vandana Abramson, MD, MSTR's Radar Profile
Review this expert's litigation history, supporting legal docs, publications, professional background, and more.
Comprehensive data on expert witnesses: Access detailed litigation history and performance metrics.
Swift assessment: Quickly evaluate an expert's track record.
Informed decisions: Make better choices when selecting or challenging expert witnesses in any case.
Expert Witness Activity
Plaintiff Cases
Defense Cases
Expert Challenges
Deposition Transcripts
Publications
106
Media & News
694
Social Media Mentions
Expert Institute operates independently and objectively as an expert witness data provider. Expert Institute does not employ, endorse, or have an affiliation with any expert witnesses for which data is provided.
Case Name | Role | Filed Date |
---|---|---|
James Archuleta, et al. v. Cibola General Hospital Co., et al. | Expert Witness | 2017-07-25 |
Radar monitors both national and state court systems to track litigation activity and access court documents.
View case details, documents, plaintiff and defense representation, defendants, judges, jurisdiction, and more.
Defense
Plaintiff
0
25
50
75
100
2000
0
2002
0
2004
0
2006
0
2008
0
2010
0
0
25
50
75
100
Radar found 106 records
Title | Type |
---|---|
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage i Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses from ATEMPT | Journal Article |
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105) | Journal Article |
Breast Cancer, Version 3.2024 | Journal Article |
Radar monitors a wide array of publication sources, including links to abstracts.
Review book chapters, journal articles, research papers, trade publications, technical reports, conference proceedings, and more.
Radar found 694 records
Title | Description |
---|
Radar scours thousands of media and news sources across the internet 24/7.
Access interviews, webinars, TV appearances, blog posts, columns, whitepapers, PDFs, profressional profiles, and more.
Institution | Degree Type |
---|---|
University of California, Berkeley | Bachelor of Arts |
University of Chicago Pritzker School of Medicine | Doctor of Medicine |
University of Pennsylvania | Master of Science in Translational Research |
Title | Employer |
---|---|
Physician | Vanderbilt Health (Nashville, TN) |
Interim Co-Leader | Vanderbilt-Ingram Cancer Center (Nashville, TN) |
Leader | Vanderbilt-Ingram Cancer Center (Nashville, TN) |
Access detailed litigation history and performance metrics.
Access your Radar profile through Expert iQ, our secure, cloud-based platform that hosts AI-driven insights.
Delivered in 5–7 business days
Receive your profile swiftly, with Radar gathering intelligence from thousands of data points.
24/7 monitoring for 12 months
Stay informed with continuous monitoring and live alerts, ensuring your profile is always up-to-date.